Supporting this, Wu et al (93) demonstrated that CLDN6 inhibits breast cancer cell invasion and metastasis via activation of the p38 MAPK signaling pathway; pharmacological inhibition of this pathway reversed CLDN6-mediated suppression of tumor aggressiveness. Here, CLDN6 is linked to breast carcinoma.